Efficacy by ulcer type and safety of lipo-PGE1 for japanese patients with diabetic foot ulcers

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 8, 2010, Pages 805-816

  Miyata, Tetsuro ^a   Yamada, Nobuhiro ^b   Miyachi, Yoshiki ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Diabetic foot ulcer; Post marketing survey

Indexed keywords

LIPOPROSTAGLANDIN E1; PROSTAGLANDIN E1;

ADOLESCENT; ADULT; ARTICLE; DIABETIC FOOT; DISEASE SEVERITY; DRUG TOLERABILITY; FEMALE; HUMAN; ISCHEMIA; JAPAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT SAFETY; PROSPECTIVE STUDY; RISK REDUCTION; THERAPY EFFECT;

EID: 77957227778     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.3608     Document Type: Article

References (22)

1. Mizushima Y, Yanagawa A, Hoshi K: Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man. J Pharm Pharmacol, 1983; 35: 666-667
2. Miyata T, Akagi D, Yamamoto K, Hosaka A, Miyahara T, Saito K, Kanetaka T, Nakazawa T, Okamoto H, Shigematsu K, Koyama H, Shigematsu H, Nagawa H: From the standpoint of vascular surgery. Diabetic Complications, 2004; 18:154-156 (in Japanese)
3. Probal K. Moulik, Robert Mtonga, Geoffrey V. Gill: Amputation and Mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care, 2003; 26: 491-494
4. Toyota T, Ikeda Y, Matsuoka K, Sakuma A: Clinical assessment of lipo PEG1 for diabetic neuropathy and skin ulcers: A multicenter, collaborative, double-blind, placebo- controlled study. J Clin Exper Med, 1990; 155: 749-769 (in Japanese)
5. Hirata Y, Ikeda Y, Matsuoka K, Tanaka T: Clinical assessment of the lipo PEG1 injection for diabetic neuropathy and skin ulcers/gangrenes: A multicenter controlled study using an existing PGE1 preparation, J Adult Dis, 1987; 17: 161-181 (in Japanese)
6. Imano E, Yoshioka R, Nakatani Y, Arai K, Motomura M, Kanda T, Yamasaki Y, Hori M: QT dispersion is increased in diabetic patients with foot ulcer. Journal of Atherosclerosis and Thrombosis, 2000; 6: 13-17
7. Tachibana T, Matsui Y, Sugama J, Nakayama T, Yoshida K, Tachi M, Tokunaga K, Miyachi Y, Sanada H, Furue M: Academic education committee report: Revision of DESIGN. J Jpn Soc Presser Ulcers, 2008; 10: 586-596 (in Japanese)
8. International Working Group on the Diabetic Foot. Epidemiology of diabetic foot infections in a population based cohort. Paper presented at: International Consensus on the Diabetic Foot; May 22-24, 2003; Noordwijkerhout, the Netherlands
9. Lavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJ: Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care, 2003; 26: 1435-1438
10. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, Wagner EH: Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care, 1999; 22: 382-387
11. Tennvall GR, Apelqvist J, Eneroth M: Costs of deep foot infections in patients with diabetes mellitus. Pharmacoeconomics, 2000; 18: 225-238
12. The International Working Group on the Diabetic Foot, The diabetic foot ulcer: outcome and management. In: International Consensus on the Diabetic Foot. pp48-54, International Working Group on the Diabetic Foot, Amsterdam, the Netherlands, 1999
13. Yagihashi A: Early diagnosis and advances in the treatment of diabetic neuropathy. J Clin Exper Med, 2007; 220: 1201-1206 (in Japanese)
14. Hamano T, Shintome M, Watanabe M: Vasodilating activity of lipo PEG1. Clin Report, 1986; 20: 5145-5154 (in Japanese)
15. Katori M, Hatanaka K: Inhibitory Mechanism of lipo prostaglandin E1. J Jap Coll Angiol, 1994; 34: 409-413
16. Sim AH, McCraw AP, Cleland ME, Aihara H, Otomo S, Hosoda K: The effect of prostaglandin E1 incorporated in lipid microspheres on thrombus formation and thrombus disaggregation and its potential to target to the site of vascular lesions. Arzneimittel Forschung/Drug Research, 1986; 36: 1206-1209
17. Uchida T, Sho T, Yamamoto K, Hayashi K, Kubo T, Shintome M, Watanabe M: Healing effects of lipo PEG1 on diabetic ulcers. Clin Report, 1995; 29: 899-905
18. Yamaguchi H, Furukawa K, Takahashi M: Erythrocyte deformability and effects of prostaglandin E1 in chronic arterial obstructive disease. Gendai Iryo, 1985; 17: 447-450 (in Japanese)
19. Ozeki Y: Drugs that affect the filterability of leukocytes. J Tokyo Women's Med Univ, 1995; 64: 208-214
20. Marchesi S, Pasqualini L, Lombardini R, Vaudo G, Lupattelli G, Pirro M, Schillaci G, Mannarino E: Prostaglandin E1 improves endothelial function in critical limb ischemia. J Cardiovasc Pharmacol, 2003; 41: 249-253
21. Matsui K, Ikeda U, Marukami Y, Yoshioka T, Shimada K: Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease. Am Heart J, 2003; 145: 330-333
22. Brevetti G, Silvestro A, Giacomo SD, Bucur R, Donato AD, Schiano V, Scopacasa F: Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg, 2003; 38: 374-379